{"altmetric_id":3715866,"counts":{"readers":{"mendeley":92,"citeulike":0,"connotea":0},"blogs":{"unique_users_count":2,"unique_users":[56693,59156],"posts_count":2},"policy":{"unique_users_count":1,"unique_users":["nap"],"posts_count":1},"total":{"posts_count":3}},"citation":{"abstract":"Desmoteplase is a novel plasminogen activator with favorable features in vitro compared with available agents. This study evaluated safety and efficacy of intravenous (IV) desmoteplase in patients with perfusion\/diffusion mismatch on MRI 3 to 9 hours after onset of acute ischemic stroke.","abstract_source":"pubmed","altmetric_jid":"4f6fa5eb3cf058f610005cfc","authors":["Anthony J. Furlan","Dirk Eyding","Gregory W. Albers","Yasir Al-Rawi","Kennedy R. Lees","Howard A. Rowley","Christian Sachara","Mariola Soehngen","Steven Warach","Werner Hacke","for the DEDAS Investigators","Furlan AJ","Eyding D","Albers GW","Al-Rawi Y","Lees KR","Rowley HA","Sachara C","Soehngen M","Warach S","Hacke W","A. J. Furlan","D. Eyding","G. W. Albers","Y. Al-Rawi","K. R. Lees","H. A. Rowley","C. Sachara","M. Soehngen","S. Warach","W. Hacke"],"doi":"10.1161\/01.str.0000217403.66996.6d","endpage":"1231","first_seen_on":"2015-02-20T00:08:38+00:00","isbns":[],"issns":["1524-4628","0039-2499"],"issue":"5","journal":"Stroke","last_mentioned_on":1467217560,"links":["http:\/\/stroke.ahajournals.org\/content\/37\/5\/1227.abstract","http:\/\/stroke.ahajournals.org\/content\/37\/5\/1227.full.pdf","http:\/\/dx.doi.org\/10.1161\/01.STR.0000217403.66996.6d","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16574922"],"pdf_url":"http:\/\/stroke.ahajournals.org\/content\/37\/5\/1227.full.pdf","pmid":"16574922","pubdate":"2006-05-01T00:00:00+00:00","publisher":"American Heart Association, Inc.","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Cardiovascular Medicine And Haematology","scheme":"era"},{"name":"Neurosciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"startpage":"1227","subjects":["brain"],"title":"Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS) Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset","type":"article","uri":"http:\/\/stroke.ahajournals.org\/cgi\/doi\/10.1161\/01.STR.0000217403.66996.6d","volume":"37","mendeley_url":"http:\/\/www.mendeley.com\/research\/dose-escalation-desmoteplase-acute-ischemic-stroke-dedas-evidence-safety-efficacy-3-9-hours-after-st"},"altmetric_score":{"score":13.08,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":13.08},"context_for_score":{"all":{"total_number_of_other_articles":7965219,"mean":6.7280072798953,"rank":595990,"this_scored_higher_than_pct":92,"this_scored_higher_than":7368615,"rank_type":"exact","sample_size":7965219,"percentile":92},"similar_age_3m":{"total_number_of_other_articles":209420,"mean":9.0255170447763,"rank":22583,"this_scored_higher_than_pct":89,"this_scored_higher_than":186821,"rank_type":"exact","sample_size":209420,"percentile":89},"this_journal":{"total_number_of_other_articles":5605,"mean":10.294723054961,"rank":728,"this_scored_higher_than_pct":87,"this_scored_higher_than":4877,"rank_type":"exact","sample_size":5605,"percentile":87},"similar_age_this_journal_3m":{"total_number_of_other_articles":136,"mean":12.402,"rank":32,"this_scored_higher_than_pct":76,"this_scored_higher_than":104,"rank_type":"exact","sample_size":136,"percentile":76}}},"demographics":{"users":{"mendeley":{"by_status":{"Unspecified":2,"Professor > Associate Professor":14,"Student  > Doctoral Student":4,"Researcher":21,"Student  > Ph. D. Student":17,"Student  > Postgraduate":6,"Other":10,"Student  > Master":8,"Student  > Bachelor":6,"Lecturer > Senior Lecturer":1,"Professor":3},"by_discipline":{"Design":1,"Engineering":2,"Medicine and Dentistry":66,"Neuroscience":2,"Immunology and Microbiology":2,"Agricultural and Biological Sciences":10,"Computer Science":1,"Biochemistry, Genetics and Molecular Biology":1,"Unspecified":7}}},"geo":{"mendeley":{"CA":2,"CO":1,"NL":1,"US":1,"BR":1,"GB":1,"IT":1,"CH":1}}},"posts":{"blogs":[{"title":"A Close Examination of Recent Studies of Endovascular Treatment for Acute Ischemic Stroke","url":"http:\/\/www.cardioexchange.org\/voices\/a-further-examination-of-mr-clean\/","citation_ids":[2996604,2887180,1227935,410705,530473,3715865,3715866,253320],"posted_on":"2015-02-19T20:15:00+00:00","summary":"Rory Spiegel takes a close look at the MR CLEAN, EXTEND-IA, and ESCAPE trials.The post A Close Examination of Recent Studies of Endovascular Treatment for Acute Ischemic Stroke appeared first on CardioExchange.","author":{"name":"CardioExchange","url":"http:\/\/www.cardioexchange.org\/","description":"An NEJM Practice Community"}},{"title":"Stroke 2.0: Novel methods of Detection, Selection and Intervention in Acute Cerebral Ischemia","url":"http:\/\/www.clinicalcorrelations.org\/?p=9038","license":"public","citation_ids":[1334056,2057548,410705,559706,2296754,2470454,9352738,9352755,660104,659832,559706,895936,895936,1508220,1508220,9352813,2967727,3804107,8257052,9352849,9352861,3715866,3715865,806490,9352904,2996604,2996604,4225187,914141,3747024,867406,1734188,4760949,9352933,9352938,9352938,9352951,9352951,9352973,9352978,9352985],"posted_on":"2016-06-29T16:26:00+00:00","summary":"By David Valentine, MD\nPeer Reviewed\nStroke is among the costliest disorders in the world for both individuals and society. Every hour of an evolving stroke kills 120 million neurons, destroys 830 billion synapses and degrades 714 kilometers of myelinated","author":{"name":"Clinical Correlations","url":"http:\/\/www.clinicalcorrelations.org","description":"The NYU Langone Online Journal of Medicine"}}],"policy":[{"title":"Neuroscience Biomarkers and Biosignatures: Converging Technologies, Emerging Partnerships: Workshop Summary","url":"https:\/\/www.nap.edu\/download\/11947","license":"public","citation_ids":[15020163,15020166,1523341,15019383,15020170,1214292,15020172,15010864,5740430,5741450,136709,4181463,15020183,133726,705340,410705,15020186,15020191,114811,14707652,3362283,15020196,148357,5760400,20474933,147848,15004379,3469016,5900052,1377164,125897,15020201,1131864,1260620,145856,15020205,16694994,15020208,5334347,4155133,148233,15020211,15020213,15020214,3715866,790625,15020217,4419148,15020220,15020223,3181696,148232,3866100,2251286,210373,10199579,3241171,15020228,15020229,15020232],"posted_on":"2008-01-01T00:00:00+00:00","source":{"name":"National Academies Press","description":"The US National Academies Press (NAP) was created by the National Academy of Sciences to publish the reports of the National Academies of Sciences, Engineering and Medicine, operating under a charter granted by the Congress of the United States. The NAP publishes on a wide range of topics in science, engineering, and medicine, providing authoritative information on important matters in science and health policy.","geo":{"country":"US"}},"page_url":"https:\/\/www.nap.edu\/catalog\/11947\/neuroscience-biomarkers-and-biosignatures-converging-technologies-emerging-partnerships-workshop-summary","collections":[],"author":{"image":"https:\/\/s3.amazonaws.com\/cache.altmetric.com\/policy\/thumbnails\/thumbnail-e3f69556a227867b1b9c4c76f17a3415e10421ec825f85fd1496fad3bf62d3d7.jpg"}}]}}